RLLVF:OTC-Relevium Technologies Inc (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 0

Change

0.00 (0.00)%

Market Cap

USD 5.33M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Relevium Technologies Inc. engages in the identification, evaluation, acquisition, and operation of brands and businesses in the health and wellness markets with a focus on e-commerce. The company markets dietary supplements, nutraceuticals, sports nutrition products, and cosmeceuticals primarily through its Bioganix brand portfolio online; dietary supplements under the LeefyLyfe brand; and skin care products under the Push & Pull System brand. It also provides Relevium Senior, a geriatric brand targeting inflammatory conditions, including joints, heart, and brain; and Relevium Kids, a pediatric brand of nutraceuticals and oral nutritional supplements. The company was formerly known as BIOflex Technologies Inc. and changed its name to Relevium Technologies Inc. in December 2015. Relevium Technologies Inc. is headquartered in Montreal, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
JDHIY JD Health International Inc

N/A

USD 12.19B
JDHIF JD Health International Inc

N/A

USD 10.00B
ALBHF Alibaba Health Information Tec..

+0.01 (+1.14%)

USD 8.29B
RADLY Raia Drogasil SA ADR

-0.51 (-14.09%)

USD 7.12B
CLCGY Clicks Group Ltd

-1.88 (-4.56%)

USD 5.27B
SHPPF Shop Apotheke Europe N.V

N/A

USD 3.20B
SAEYY Shop Apotheke Europe N.V

N/A

USD 2.88B
NOTR Nowtransit Inc

N/A

USD 0.55B
ZRSEF Zur Rose Group AG

N/A

USD 0.46B
PNPL Pineapple Express

N/A

USD 0.01B

ETFs Containing RLLVF

VXC:CA Vanguard FTSE Global All .. 23.78 % 0.27 %

+0.55 (+0.20%)

CAD 2.24B
VEQT:CA Vanguard All-Equity ETF P.. 16.26 % 0.25 %

+0.31 (+0.20%)

CAD 5.91B
VGRO:CA Vanguard Growth Portfolio 13.12 % 0.25 %

+0.18 (+0.20%)

CAD 6.30B
VBAL:CA Vanguard Balanced Portfol.. 9.90 % 0.25 %

+0.11 (+0.20%)

CAD 3.32B
VCNS:CA Vanguard Conservative ETF.. 6.67 % 0.25 %

+0.08 (+0.20%)

CAD 0.52B
VCIP:CA Vanguard Conservative Inc.. 3.48 % 0.25 %

+0.04 (+0.20%)

CAD 0.23B
VI:CA Vanguard FTSE Developed A.. 0.00 % 0.23 %

+0.13 (+0.20%)

N/A
VRIF:CA Vanguard Retirement Incom.. 0.00 % 0.00 %

+0.05 (+0.20%)

CAD 0.28B

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -30.35% 13% F 7% C-
Dividend Return -30.35% 13% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 61.68% 63% D 45% F
Risk Adjusted Return -49.20% 25% F 14% F
Market Capitalization 5.33M 50% F 33% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.